ABSTRACT
The ongoing pandemic of severe acute respiratory coronavirus 2 (SARS-CoV-2) is causing a devastating impact on public health worldwide. However, details concerning the profound impact of SARS-CoV-2 on host cells remain elusive. Here, we investigated the effects of SARS-CoV-2-encoded viral proteins on the intracellular activity of long interspersed element 1 (L1) retrotransposons using well-established reporter systems. Several nonstructural or accessory proteins (Nsps) of SARS-CoV-2 (i.e., Nsp1, Nsp3, Nsp5, and Nsp14) significantly suppress human L1 mobility, and these viral L1 inhibitors generate a complex network that modulates L1 transposition. Specifically, Nsp1 and Nsp14 inhibit the intracellular accumulation of L1 open reading frame proteins (ORF1p), whereas Nsp3, Nsp5, and Nsp14 repress the reverse transcriptase activity of L1 ORF2p. Given recent findings concerning the roles of L1 in antiviral immune activation and host genome instability, the anti-L1 activities mediated by SARS-CoV-2-encoded inhibitors suggest that SARS-CoV-2 employs different strategies to optimize the host genetic environment.
ABSTRACT
This dissertation focuses on the analysis and estimation of Coca-Cola Company's stock prices, growth rate and market value in the future by studying its current and past data as well as learning and evaluating the global economic and political circumstances. The CAPM (Capital Asset Pricing Model) and WACC (weighted Average Cost of Capital), are applied in terms of fulfilling the prerequisite of using the DCF (Discounted Cash Flow Model) and the Company Comparable Analysis, which enables the team to obtain a result that regarding the future extent of the global pandemic - COVID-19 and the international relationship -especially between the US and China. The growth rate of the Coca-Cola Company's earning per share is estimated to be in a range of 0.14% to 11.18% by using the comparable analysis, and the firm's free cash flow growth rate at the perpetuity stage is estimated at a range of 1.8% to 3.2% by using the DCF in the following year. As for the stock price, the company is only overvalued when the growth rate is lower or equal to 1.8%. Overall, despite a few assumptions that could affect the result, it is concluded that the company is very likely to experience growth in the future, and it is suggested to hold some stocks of this company.